US Bancorp
ONCT

US Bancorp’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

US Bancorp’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$760 – 4236
2024
Q2 		$760 Buy
+100
New +$861 ﹤0.01% 3834

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

US Bancorp's ONCT Position: Q3 2024 in Review

US Bancorp sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2024, closing a stake of 100 shares — an estimated $760 sold.

US Bancorp first reported a position in ONCT in Q2 2024 and held it in 1 quarter. The position peaked at $760 in Q2 2024. 23 funds tracked by Wall St. Rank hold ONCT as of Q3 2024.

  • US Bancorp reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • US Bancorp sold 100 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $760.
  • US Bancorp first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • US Bancorp's Oncternal Therapeutics, Inc. Common Stock position peaked at $760 in Q2 2024.
  • 23 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2024.

Based on US Bancorp's 13F filing for Q3 2024, filed 28 Oct 2024.